1-Chloro-2-(2,2-Dichloro-1-(4-Chlorophenyl)Ethyl)Benzene 1-氯-2-(2,2-二氯-1-(4-氯苯基)乙基)苯

CAS 53-19-0 MFCD00000850

化学结构图

53-19-0
SMILES: Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1

化学属性

Mol. Formula(ClC6H4)2CHCHCl2
Mol. Weight320
Melting Point76-78 °C
Appearance 白色结晶。熔点76-78℃。溶于乙醇和四氯化碳。
SolubilitySoluble in DMSO (≥ 64 mg/ml), ethanol (≥ 64 mg/ml), and water (< 1 mg/ml).,
Density1.372

别名和识别编码

Chemical Name1-Chloro-2-(2,2-Dichloro-1-(4-Chlorophenyl)Ethyl)Benzene
Synonym 'LGC' (1126) (2,4'-DICHLORODIPHENYL)DICHLOROETHANE 1,1-DICHLORO-2-(2-CHLOROPHENYL)-2 1,1-DICHLORO-2-(O-CHLOROPHENYL)-2-(P-CHLOROPHENYL)ETHANE 1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane 1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane 1,1-dichloro-2,2-bis(2,4'-dichlorophenyl)ethane 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-ethan 1,1-二氯-2-(2-氯苯基)-2-(4-氯苯基)乙烷 1-(2-CHLOROPHENYL)-1-(4-CHLOROPHENYL)-2,2-DICHLOROETHANE 1-(2-氯苯基)-1-(4-氯苯基)-2,2-二氯乙烷 1-(o-Chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene 2,2-(2-chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane 2,4'-D 2,4'-DDD 2,4'-Ddd
MDL NumberMFCD00000850
CAS Number53-19-0
PubChem Substance ID4211
Beilstein Registry Number2056007
EC Number200-166-6
Chemical Name Translation1-氯-2-(2,2-二氯-1-(4-氯苯基)乙基)苯
Merck Number13,6237 / 13,6237
Wiswesser Line NotationGYGYR BG&R DG
LabNetwork Molecule IDLN01289322
InChIInChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
信息真实价格透明    资金保障    专业采购外包团队在线服务   
信息真实价格透明    资金保障    专业采购外包团队在线服务   
品牌质保精细包装    现货库存    一流品牌服务   

分类

  • {SNA} Alphabetical Index of Analytical Standards, Method and Regulation Specific, Analytical Standards, Analytical/Chromatography, Bioactive Small Molecules, Cell Biology, D, D-DIF, DA - DH, Oeko-Tex Standard 100, Pesticides
  • {SNA} Bioactive Small Molecule Alphabetical Index, C-CH, 生物活性小分子, 细胞生物学
  • {SNA} Bioactive Small Molecules, C-CH, Cell Biology

产品应用

  • An adrenal cytotoxic agent.

相关文献及参考

  • Merck:13,6237 / 13,6237 Beilstein: 5,IV,1883

安全信息

GHS Symbol
Precautionary statements
  • P201 Obtain special instructions before use. 使用前获取专门指示。
  • P202 Do not handle until all safety precautions have been read and understood. 已阅读并理解所有的安全预防措施之前，切勿操作。
  • P260 Do not breathe dust/fume/gas/mist/vapours/spray. 不要吸入粉尘/烟/气体/烟雾/蒸汽/喷雾。
  • P261 Avoid breathing dust/fume/gas/mist/vapours/spray. 避免吸入粉尘/烟/气体/烟雾/蒸汽/喷雾。
  • P264 Wash hands thoroughly after handling. 处理后要彻底洗净双手。
  • P270 Do not eat, drink or smoke when using this product. 使用本产品时不要吃东西，喝水或吸烟。
  • P271 Use only outdoors or in a well-ventilated area.? 只能在室外或通风良好的地方使用。
  • P280 Wear protective gloves/protective clothing/eye protection/face protection. 戴防护手套/防护服/眼睛的保护物/面部保护物。
  • P281 Use personal protective equipment as required. 使用所需的个人防护装备。
  • P304+P340
  • P307+P311
  • P308+P313
  • P312 Call a POISON CENTER or doctor/physician if you feel unwell. 如果你感觉不适，呼叫解毒中心或医生/医师。
  • P314 Get medical advice/attention if you feel unwell. 获取医疗咨询/就医，如果你觉得不舒服
  • P321 Specific treatment (see … on this label). 具体治疗（见本标签上的）。
  • P403+P233
  • P405 Store locked up. 上锁保管。
  • P501 Dispose of contents/container to..… 处理内容物/容器.....
Hazard statements
  • H351 Suspected of causing cancer 怀疑致癌
WGK Germany3
RTECSKH7880000
Personal Protective Equipment Eyeshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges dust mask type N95 (US), Eyeshields, Gloves
Signal word Warning
Safety Statements
  • S36/37 Wear suitable protective clothing and gloves 穿戴适当的防护服和手套；
Hazard Codes Xn
Risk Statements
  • R40 Limited evidence of a carcinogenic effect 有限证据表明其致癌作用
Packing GroupIII
Hazard Class6.1(b)
Storage condition APPROX 4°C
UN Number 3249 
TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Intraperitoneal
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : 2500 mg/kg/7W-I
TOXIC EFFECTS :
   Tumorigenic - equivocal tumorigenic agent by RTECS criteria
   Blood - lymphoma, including Hodgkin's disease
   Skin and Appendages - tumors
REFERENCE :
   CANCAR Cancer (Philadelphia).  (Lippincott/Harper, Journal Fulfillment
   Dept., 2350 Virginia Ave., Hagerstown, MD 21740)  V.1-    1948-
   Volume(issue)/page/year: 40,1935,1977

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Intraperitoneal
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 9750 mg/kg/26W-I
TOXIC EFFECTS :
   Tumorigenic - equivocal tumorigenic agent by RTECS criteria
   Lungs, Thorax, or Respiration - tumors
   Blood - lymphoma, including Hodgkin's disease
REFERENCE :
   CANCAR Cancer (Philadelphia).  (Lippincott/Harper, Journal Fulfillment
   Dept., 2350 Virginia Ave., Hagerstown, MD 21740)  V.1-    1948-
   Volume(issue)/page/year: 40,1935,1977

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : 10 gm/kg/52W-C
TOXIC EFFECTS :
   Tumorigenic - equivocal tumorigenic agent by RTECS criteria
   Reproductive - Tumorigenic effects - testicular tumors
REFERENCE :
   BAFEAG Bulletin de l'Association Francaise pour l'Etude du Cancer.  (Paris,
   France)  V.1-52, 1908-65. For publisher information, see BUCABS.
   Volume(issue)/page/year: 52,89,1965

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - man
DOSE/DURATION           : 17 gm/kg/35W
TOXIC EFFECTS :
   Behavioral - somnolence (general depressed activity)
REFERENCE :
   CANCAR Cancer (Philadelphia).  (Lippincott/Harper, Journal Fulfillment
   Dept., 2350 Virginia Ave., Hagerstown, MD 21740)  V.1-    1948-
   Volume(issue)/page/year: 42,2177,1978

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - woman
DOSE/DURATION           : 11 gm/kg/15W
TOXIC EFFECTS :
   Vascular - BP lowering not characterized in autonomic section
   Blood - normocytic anemia
   Blood - pigmented or nucleated red blood cells
REFERENCE :
   CANCAR Cancer (Philadelphia).  (Lippincott/Harper, Journal Fulfillment
   Dept., 2350 Virginia Ave., Hagerstown, MD 21740)  V.1-    1948-
   Volume(is

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - woman
DOSE/DURATION           : 14 gm/kg/22W
TOXIC EFFECTS :
   Behavioral - somnolence (general depressed activity)
   Gastrointestinal - hypermotility, diarrhea
   Gastrointestinal - nausea or vomiting
REFERENCE :
   CANCAR Cancer (Philadelphia).  (Lippincott/Harper, Journal Fulfillment
   Dept., 2350 Virginia Ave., Hagerstown, MD 21740)  V.1-    1948-
   Volume(issue)/page/year: 42,2177,1978

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - woman
DOSE/DURATION           : 800 mg/kg/4D
TOXIC EFFECTS :
   Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
   CANCAR Cancer (Philadelphia).  (Lippincott/Harper, Journal Fulfillment
   Dept., 2350 Virginia Ave., Hagerstown, MD 21740)  V.1-    1948-
   Volume(issue)/page/year: 42,2177,1978

TYPE OF TEST            : Cytogenetic analysis
TEST SYSTEM             : Rodent - rat Cells - not otherwise specified
DOSE/DURATION           : 10 ug/L
REFERENCE :
   34LXAP "Insecticide Biochemistry and Physiology," Wilkinson, C.F., ed., New
   York, Plenum Pub. Corp., 1976  Volume(issue)/page/year: -,555,1976

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Subcutaneous
SPECIES OBSERVED        : Rodent - mouse
DOSE                    : 900 mg/kg
SEX/DURATION            : female 6-14 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Specific Developmental Abnormalities - Central Nervous System
   Reproductive - Specific Developmental Abnormalities - eye/ear
   Reproductive - Specific Developmental Abnormalities - craniofacial
   (including nose and tongue)
REFERENCE :
   NTIS** National Technical Information Service.  (Springfield, VA 22161)
   Formerly U.S. Clearinghouse for Scientific & Technical Information.
   Volume(issue)/page/year: PB223-160

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - man
DOSE                    : 16 gm/kg
SEX/DURATION            : male 15 week(s) pre-mating
TOXIC EFFECTS :
   Reproductive - Paternal Effects - spermatogenesis (incl. genetic material,
   sperm morphology, motility, and count)
   Reproductive - Paternal Effects - testes, epididymis, sperm duct
REFERENCE :
   JTCTDW Journal of Toxicology, Clinical Toxicology.  (Marcel Dekker, 270
   Madison Ave., New York, NY 10016)  V.19-    1982-  Volume(issue)/page/year:
   25,463,1987

TYPE OF TEST            : TDLo - Lowest published toxi

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rat
DOSE                    : 250 mg/kg
SEX/DURATION            : female 15-19 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Specific Developmental Abnormalities - endocrine system
   Reproductive - Specific Developmental Abnormalities - urogenital system
REFERENCE :
   BNEOBV Biology of the Neonate.  (S. Karger Pub., Inc., 79 Fifth Ave., New
   York, NY 10003) V.15-    1970-  Volume(issue)/page/year: 26,283,1975

其他信息

  • 药理作用:米托坦结构与杀虫药滴滴涕(DDT)和DDD相似,它能选择性地使肾上腺皮质束状带及网状带细胞萎缩、坏死，但不影响球状带，故醛固酮分泌不受影响。用药后血、尿中氢化可的松及其代谢物迅速减少,体内肾上腺皮质激素及其代谢产物水平迅速下降，适用于治疗无法手术的、功能性和非功能性肾上腺皮质癌、肾上腺瘤、肾上腺增生引起的枯氏综合征、肾上腺皮质增生、皮质癌术后辅助治疗以及肿瘤所致的皮质醇增多症。 口服约40%由胃肠道吸收，其余60%以原型随粪便排出。每日5～10g，血药浓度可达10～90μg/ml，代谢物浓度30～50μg/ml。停药6～9周后，血浆中仍可测到邻氯烷。米托坦脂溶性高，主要储存于脂肪中。从尿中排出的水溶性代谢物约占给药量的25%。
  • MOL 文件:53-19-0.mol
  • 可燃性危险特性:热分解排出有毒氯化物烟雾
  • 类别:有毒物质
  • Sigma Aldrich:53-19-0(sigmaaldrich)
  • 图谱信息:米托坦(53-19-0)红外图谱(IR2) 米托坦(53-19-0)核磁图( 13 CNMR) 米托坦(53-19-0)红外图谱(IR1) 米托坦(53-19-0)核磁图( 1 HNMR) 米托坦(53-19-0)Raman光谱 米托坦(53-19-0)质谱(MS)
  • 毒性分级:中毒
  • 储运特性:库房低温通风干燥
  • MSDS 信息:2,2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane(53-19-0).msds
  • 急性毒性:口服-大鼠 LD50: >; 5000 毫克/公斤; 口服-小鼠 LD50: >; 4000 毫克/公斤
  • Mitotane 是一种抗肿瘤药，用于治疗肾上腺皮质癌。
  • 溶于乙醇和四氯化碳。
  • 用途一:抗肿瘤药，用于治疗肾上腺皮质癌。
  • 方法一:由邻溴氯苯（见05820）经下述步骤制得。
  • 灭火剂:水,二氧化碳, 泡沫, 干粉
  • 上游原料:2-溴氯苯
  • 用途二:抗肿瘤药，用于治疗肾上腺皮质癌

系列性分类

  1. Life Science 生命科学
  2. Cell Biology 细胞生物学
  3. Bioactive Small Molecules - Cell Biology
  4. C-CH - Bioactive Small Molecules
  1. Life Science 生命科学
  2. Cell Biology 细胞生物学
  3. Bioactive Small Molecules - Cell Biology
  4. D-DIF - Bioactive Small Molecules
  1. Analytical & Chromatography 分析化学与色谱
  2. Analytical Standards
  3. Method Specific - Analytical Standards
  4. Oeko-Tex Standard 100 - Method Specific
  5. Pesticides - Oeko-Tex Standard 100
  1. Chemical Synthesis 化学合成
  2. Building Blocks 合成砌块
  3. Organic Building Blocks 有机砌块
  4. Halogenated Hydrocarbons 卤代烃
  5. Aryl 芳基卤代烃
  6. C13 to C37+ - Aryl
  1. Analytical & Chromatography 分析化学与色谱
  2. Analytical Standards
  3. Alphabetic - Analytical Standards
  4. D - Alphabetic
  5. DA - DH - D

相关产品推荐